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Abstract
Introduction: Polycystic ovary syndrome (PCOS) is characterised by increased frequency of hypothalamic GnRH pulses leading to
a relative increase in LH synthesis by the pituitary. As GnRH stimulation can reveal a relative LH excess, we have endeavoured to assess
whether GnRH test might be useful in the diagnosis of PCOS.
Material and methods: The study involved 185 subjects: a PCOS group, n = 151, all with oligo- or amenorrhoea, aged (mean ± SD) 24.8 ±
± 5.4 years, BMI 24.5 ± 6.0 kg/m2; and regularly menstruating controls, n = 34, aged 26.6 ± 5.0 years, BMI 24.6 ± 5.5 kg/m2. In 121 subjects
with PCOS and in 32 controls, serum LH and FSH were measured before (0 minutes) and 30 and 60 minutes after GnRH stimulation
(100 µg i.v.). Insulin resistance was assessed by HOMA and Insulin Resistance Index derived from glucose and insulin concentrations
during 75 gram oral glucose tolerance test.
Results: Women with PCOS had higher testosterone (p = 0.0002), androstendione (p = 0.0021), 17OH-progesterone (p < 0.0001) and were
more insulin resistant. Raised concentrations of at least one androgen were, however, found only in 58.1% of women with PCOS. Baseline
and stimulated LH concentrations were higher in PCOS (9.09 ± 5.56 vs 4.83 ± 1.71 IU/L, 35.48 ± 31.4 vs 16.30 ± 6.68 IU/L, 33.86 ± 31.8 vs
13.45 ± 5.2 IU/L, at 0, 30 and 60 mins post GnRH, respectively, p < 0.0001). There was no difference in baseline or stimulated FSH concen-
trations between groups. Relative increases of LH or FSH in comparison to respective baseline values were similar in both groups. There
was, however, a marked increase in LH/FSH ratio in PCOS in comparison to controls (LH0 min/FSH0 min 1.59 ± 0.95 vs 0.76 ± 0.2, LH30 min/
/FSH30 min 4.07 ± 3.0 vs 1.89 ± 0.79, LH60 min/FSH60 min 3.56 ± 2.58 vs 1.55 ± 0.63, p < 0.0001 at all time points). Further analysis revealed that
LH30 min/FSH30 min > 2.11 or LH60 min/FSH60 min > 1.72 had 78.3% and 87.5% sensitivity and 81.7% and 81.3% specificity for the diagnosis of
PCOS, respectively.
Conclusions: Women with PCOS have higher baseline and GnRH-stimulated LH concentrations. GnRH stimulation results in an increase
in LH/FSH ratio in women with PCOS. Therefore we postulate that this phenomenon might be potentially useful as an additional tool in
the diagnosis of PCOS. (Pol J Endocrinol 2011; 62 (2): 120–128)
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Streszczenie
Wstep: Test z gonadoliberyną (GnRH) może ujawnić względną przewagę syntezy LH nad FSH, w wyniku zwiększonej częstości pod-
wzgórzowych pulsów GnRH w zespole policystycznych jajników (PCOS, polycystic ovary syndrome). W pracy podjęto zatem próbę oceny,
czy stymulacja przysadki przez GnRH może być przydatna w diagnostyce PCOS.
Materiał i metody: Badaniem objęto 185 osób: kobiety z PCOS, n = 151, z zaburzeniami miesiączkowania o typie oligo- lub amenorrhoea,
w wieku (średnia ± SD) 24,8 ± 5,4 lat, wskaźnikiem masy ciała (BMI, body mass index) 24,5 ± 6,0 kg/m2 oraz kobiety z grupy kontrolnej, n = 34,
wiek 26,6 ± 5,0 lat, BMI 24,6 ± 5,5 kg/m2. U 121 kobiet z PCOS oraz u 32 kobiet z grupy kontrolnej oznaczono LH i FSH przed (0 minut) oraz
w 30 i 60 minut po podaniu GnRH (100 µg i.v.). Insulinooporność oceniono za pomocą modelu HOMA oraz za pomocą indeksu insulino-
oporności (IRI), obliczanego na podstawie stężeń glukozy i insuliny w doustnym teście tolerancji glukozy (75 g).
Wyniki: Kobiety z PCOS miały wyższe stężenia testosteronu całkowitego (p = 0,0002), androstendionu (p = 0,0021), 17OH-progesteronu
(p < 0,0001) oraz charakteryzowały się większą insulinoopornością. Podwyższone stężenia któregoś z androgenów obserwowano u 58,1%
kobiet z PCOS. Wyjściowe oraz stymulowane stężenia LH były wyższe u kobiet z PCOS (9,09 ± 5,56 v. 4,83 ± 1,71 IU/L, 35,48 ± 31,4 v.
16,30 ± 6,68 IU/L, 33,86 ± 31,8 v. 13,45 ± 5,2 IU/L, odpowiednio w 0, 30 i 60 minucie testu, p < 0,0001). Nie było różnic pomiędzy wyjścio-
wymi oraz stymulowanymi stężeniami FSH między grupami. Stosunki stężeń LH oraz FSH po stymulacji przez GnRH w porównaniu
z wartościami wyjściowymi były zbliżone w obu badanych grupach. Zaobserwowano znaczący wzrost stosunku LH/FSH u kobiet
z PCOS, w porównaniu z grupami kontrolną (LH0 min/FSH0 min 1,59 ± 0,95 v. 0,76 ± 0,2, LH30 min/FSH30 min 4,07 ± 3,0 v. 1,89 ± 0,79, LH60 min/FSH60  min
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3,56 ± 2,58 v. 1,55 ± 0,63, p < 0,0001 we wszystkich punktach czasowych). Stosunek LH30 min/FSH30 min > 2,11 lub LH60 min/FSH60 min > 1,72
charakteryzował się odpowiednio czułością 78,3% i swoistością 87,5% oraz czułością 81,7% i swoistością 81,3% dla kobiet z PCOS.
Wnioski: U kobiet z PCOS stwierdza się wyższe stężenia LH, zarówno przed, jak i po stymulacji przez GnRH. Stosunek stężeń LH do FSH
ulega istotnemu zwiększeniu po stymulacji przez GnRH u kobiet z PCOS. Autorzy wnioskują, że ocena stosunku LH/FSH po stymulacji
przez GnRH może być przydatna, jako badanie dodatkowe w diagnostyce PCOS.
(Endokrynol Pol 2011; 62 (2): 120–128)
Słowa kluczowe: zespół policystycznych jajników, test GnRH, insulinooporność, oligomenorrhea
Introduction
Polycystic ovary syndrome (PCOS) is the commonest
endocrinopathy of women of reproductive age, affect-
ing 4–7% of this population [1, 2]. Clinically it can
present as oligo-/amenorrhoea, hyperandrogenism/hir-
sutism and/or fertility problems [1–3].
Current ESHRE/ASMR consensus defines PCOS by
the so-called Rotterdam criteria [4]. According to these,
PCOS can be diagnosed if a woman fulfills at least two
of three criteria: i.e. oligo/anovulation, clinical or bio-
chemical hyperandrogenism and/or polycystic ovaries
on ultrasound imaging, when other causes of menstru-
al irregularities and hyperandrogenaemia have been
ruled out [4]. In some cases, diagnosis of PCOS may be,
however, still controversial, particularly in women with
irregular periods and polycystic ovaries on ultrasound,
but with androgens within the reference range. In-
creased androgen synthesis in PCOS, both of ovarian
and adrenal origins [5], stems from abnormalities on
several levels of the hypothalamo-pituitary-ovarian axis.
The most prominent abnormality involves an increased
frequency of pituitary LH pulses resulting from an in-
creased frequency of pulsatile hypothalamic GnRH se-
cretion. The above mentioned dysfunction of hypotha-
lamic GnRH pulse generator leads to a relative increase
of LH rather than FSH secretion by the pituitary [6],
that in turn results in an increased LH-stimulated an-
drogen secretion [7, 8]. More than 20 years ago, it was
also noted that administration of a GnRH analogue al-
lows the demonstration of abnormalities of ovarian ste-
roidogenesis in PCOS, namely an increase of 17-hy-
droxy-progesterone to androstendione ratio after GnRH
stimulation [9, 10]. On the strength of that, some au-
thors [10, 11] formulated the concept of so-called func-
tional ovarian hyperandrogenism that was supposed to be
characteristic for PCOS and that could be demonstrat-
ed after stimulation by GnRH analogue (originally by
nafarelin) [9–11]. The same authors [9–11] also described
increased LH concentrations after GnRH analogue stim-
ulation, but these changes were described in a qualita-
tive, rather than a quantitative, manner. We have en-
deavoured to quantitatively investigate the issue of an
increased LH release after GnRH stimulation.
Aim of the study
The aim of the study was to assess LH and FSH secre-
tion after GnRH stimulation in women with PCOS, and
in regularly menstruating healthy controls. We decid-
ed to compare both the changes in LH and FSH con-
centrations to their respective baseline values as well
as the changes of LH/FSH ratio after GnRH stimula-
tion. Thus, we have endeavoured to assess whether
assessment of gonatrophin secretion after GnRH stim-
ulation might provide some useful information for the
diagnosis of PCOS.
Material and methods
The study involved 185 women admitted to the Depart-
ment of Endocrinology & Metabolic Diseases of the
‘Polish Mother’ Memorial Research Institute and the
Medical University of Lodz between 2006 and 2009. Of
these, 151 women aged 24.8 ± 5.4 years  (mean ± SD)
were diagnosed with PCOS according to the Rotterdam
criteria [4]. All these women had had oligo- or amenor-
rhoea and polycystic ovaries on pelvic (intravaginal)
ultrasound, while the majority also had clinical hyper-
androgenism (acne and/or hirsutism). The control group
consisted of 34 healthy, regularly menstruating, wom-
en aged 26.8 ± 5.0 years (Table I).
All hormonal investigations were performed be-
tween the third and sixth day of either a spontaneous
or a progestagen-induced menstruation (in the latter
case menstrual bleeding was typically obtained after
ten-day administration of dydrogesterone (Duphas-
ton®) or micronised progesterone (Luteina®). Endo-
crine investigations involved measurements of LH, FSH,
oestradiol, total testosterone, androstendione, di-hydro-
epinadrosterone sulphate (DHEAS), 17-hydroxy-
progesterone, TSH, free T3 and free T4. The presence
of hyperprolactinaemia was excluded after assessment
of a nine time point prolactin day curve, as previously
described [12]. Hypercortisolaemia was excluded either
on the basis of a midnight serum cortisol below 50 nmol/L
(1.8 µg/dL) or on cortisol suppression below 50 nmol/L
after an overnight 1.0 mg dexamethasone suppression
test [13]. Furthermore, in all subjects we performed
a 75 gram oral glucose tolerance test (OGTT) with glu-
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cose and insulin measurements at 0, 60 and 120 min-
utes. Subsequently, insulin resistance parameters were
calculated, i.e. HOMA, (where HOMA = fasting insu-
lin (µU/mL) × fasting glucose (mmol/L)/22.5) [14] and
an Insulin Resistance Index (IRI) based on the assess-
ment of glycaemia and insulinaemia during OGTT. The
product of the glucose area under the plasma glucose
curve and insulin area under plasma glucose curve is
used as an index of insulin resistance, calculated through
the formula: 2/[1/(INSp × GLYp)]+1, where INSp and
GLYp are the measured insulin and glycaemic areas [15].
This method has a good correlation with the gold stan-
dard of assessment of insulin resistance, i.e. the eugly-
caemic hyperinsulinaemic clamp technique [16].
Hirsutism was assessed according to the Ferriman-
Galwey scale [17], where a score above eight was con-
sidered significant. All pelvic ultrasound examinations
were performed at the Department of Ultrasound Di-
agnositics of the ‘Polish Mother’ Memorial Research
Institute, where diagnosis of polycystic ovaries was
based on the presence of either 12 or more follicles mea-
suring 2–9 mm in diameter, or increased ovarian vol-
ume (> 10 cm3) [18].
In 121 patients diagnosed with PCOS, and in 32 con-
trols, we performed a GnRH test that involved intrave-
nous administration of 100 µg of synthetic GnRH
(Relisorm®) by Serono lub LHRH® by Ferring. Blood
samples for the measurements of LH and FSH (electro-
chemiluminescence method (ECLIA) by Elecsys 2010
analyser) were taken before (0 minutes) and 30 and
60 minutes after GnRH administration.
Statistical analysis
Depending on distribution characteristics of the analy-
sed parameters, we employed either a t-test in cases of
normal distribution or a Mann-Whitney test if distribu-
tion characteristics were not normal. Correlation anal-
ysis was performed by the means of Spearman rank
correlation method. Statistical significance was assumed
for p < 0.05. All analyses were performed using Statis-
tica 8.0 software.
Results
Women with PCOS and regularly menstruating con-
trols were matched for their age and BMI (Table I). Mean
prolactin concentrations were higher in women with
PCOS, but failed to reach statistical significance (data
not shown). As expected, women with PCOS had higher
concentrations of total testosterone, androstendione,
17-hydroxy-progesterone and oestradiol (Table II). It
should be noted, however, that androgen concentra-
tions remained within the reference range in a signifi-
cant number of women with PCOS despite, on aver-
Table II. Concentrations of selected hormones in women with PCOS and controls (CONTR)
Tabela II. Stężenia badanych hormonów u pacjentek z PCOS i w grupie kontrolnej (CONTR)
Group n Mean Median SD Min Max p value
Oestradiol  [pg/mL] CONTR 32 45.49 35.09 31.69 12.05 190.4  0.018PCOS 151 65.31 47.60 62.06 15.0 406.7
Testosterone [ng/mL] CONTR 32 0.53 0.59 0.29 0.16 1.50  0.0002PCOS 151 0.77 0.72 0.40 0.20 2.07
DHEAS [µg/dL] CONTR 32 264.5 249.7 115.3 70.4 517.7  0.38PCOS 133 288.4 261.6 129.2 70.0 662.5
Androstendione CONTR 31 2.23 2.15 0.93 0.79 5.04
 0.0021[ng/mL] PCOS 124 3.25 2.78 1.80 0.10 10.00
17OH-progesterone CONTR 30 0.54 0.46 0.23 0.10 1.30   < 0.00001[ng/mL] PCOS 120 1.25 1.00 0.93 0.30 6.29
Table I. Demographic characteristics of women with polycystic ovary syndrome (PCOS), n = 151, and regularly menstruating
controls (n = 34)
Tabela I. Statystyki opisowe dla danych demograficznych pacjentek z grupy kontrolnej (n = 34) i z PCOS (n = 151)
Group n Mean Median SD Min Max p value
Age (years) PCOS 151 24.8 24.0 5.4 16.0 49.0 0.83CONTR 34 26.8 27.0 5.0 17.0 38.0
BMI [kg/m2] PCOS 151 24.5 22.7 6.0 14.5 43.6 0.99CONTR 34 24.5 22.1 5.5 18.1 39.0
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age, higher values than in controls. In particular, raised
concentrations of total testosterone were noted only in
38.6% of women with PCOS, androstendione in 34.7%
and DHEAS in only 28.8%. Raised concentration of at
least a single androgen was observed in 58.1% of wom-
en with PCOS. Interestingly, women with PCOS also
had significantly (i.e. around two-fold) higher 17-hy-
droxysprogesterone/androstendione ratio. This was sta-
tistically highly significant (p < 0.001, see Fig. 1).
There were no differences in glucose levels during
OGTT between women with PCOS and controls; wom-
en with PCOS had, however, higher concentrations of
fasting insulin and were more insulin-resistant (IRI:
0.93 ± 0.38 v. 0.78 ± 0.34, for PCOS and controls, re-
spectively, p = 0.045). HOMA index was higher in wom-
en with PCOS, although this was of borderline statisti-
cal significance (p = 0.06) (Table III). Both baseline and
GnRH-stimulated LH concentrations were significant-
ly higher in women with PCOS, but there were no
differences in FSH concentrations between women with
PCOS and controls (Table IV, Fig. 2 and 3).
Relative proportions of GnRH-stimulated versus
baseline gonadotrophin concentrations, i.e. LH30 min/
/LH0 min, LH60 min/LH0 min, FSH30 min/FSH0 min, FSH60 min/FSH0 min,
were similar in PCOS and controls, though there was
a trend towards higher LH60 min/LH0 min ratio in women
with PCOS (3.76 ± 2.0 IU/L v. 3.28 ± 2.59 IU/L, p = 0.053),
Table V. In women with PCOS, we observed signifi-
cantly raised LH/FSH ratio at all three time-points
(Table V, Fig. 4). Furthermore, there was a further
increase in LH/FSH ratio after GnRH stimulation in
women with PCOS (Table 5, Fig. 4), i.e. baseline LH/
/FSH ratio was 1.59 ± 1.0 in PCOS and 0.79 ± 0.2 in
controls, but 4.09 ± 2.99 and 3.56 ± 2.58 for PCOS,
and 1.89 ± 0.79, and 1.55 ± 0.63 for controls at 30
and 60 minutes after GnRH stimulation, respectively
(p < 0.001, Table V, Fig. 4).
Figure 1. 17-hydroxyprogesterone [ng/mL] to androstendione [ng/mL]
ratio in women with PCOS and controls
Rycina 1. Wskaźnik stosunku stężeń 17-OH-progesteronu [ng/ml]
do androstendionu [ng/ml] w u kobiet z PCOS i w grupie
kontrolnej
Table III. Glucose, insulin and insulin resistance indices during oral glucose tolerance test (OGTT) in women with PCOS and
controls (CONTR)
Tabela III. Glikemia, insulinemia w teście OGTT oraz wskaźniki insulinooporności u kobiet z PCOS i w grupie kontrolnej
(CONTR)
Group n Mean Median SD Min Max p value
Glucose_0’ [mg/dL] PCOS 151 80.0 81.0 9.4 80.0 99.00 0.77CONTR 34 80.8 81.5 6.9 68.0 96.00
Glucose_60’ [mg/dL] PCOS 145 112.6 109.0 36.1 140.0 242.0 0.93CONTR 34 112.6 113.0 31.0 93.0 213.0
Glucose_120’ [mg/dL] PCOS 145 97.1 95.0 29.7 110.0 261.0 0.65CONTR 34 93.8 94.0 23.7 48.0 159.0
Insulin_0’ [mIU/mL] PCOS 144 8.95 6.97 6.35 0.38 41.84 0.043CONTR 34 7.34 5.51 6.54 2.00 31.92
Insulin_60’ [mIU/mL] PCOS 143 67.01 44.34 56.74 4.74 307.50 0.18CONTR 34 51.74 35.80 40.50 16.4 192.00
Insulin_120’ [mIU/mL] PCOS 143 49.81 35.43 47.86 6.10 360.00 0.61CONTR 34 44.29 31.09 51.01 13.10 300.0
IRI PCOS 132 0.93 0.84 0.38 0.15 1.88 0.045CONTR 34 0.78 0.69 0.34 0.33 1.68
HOMA [mmol/L × mIU/mL] PCOS 144 1.81 1.41 1.36 0.37 8.37 0.060CONTR 34 1.48 1.16 1.32 0.36 5.99
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Results of sensitivity and specificity analysis for LH/
/FSH ratio are presented in Table VI. Receiver operated
characteristics analysis (ROC curves) was employed in
order to define the best discriminatory cut-off point for
GnRH-stimulated LH/FSH ratio. This revealed that LH30 min/
/FSH30 min > 2.11, or LH60 min/FSH60 min > 1.72, had 78.3% sensi-
tivity and 87.5% specificity (for LH30 min/FSH30 min) as well as
81.7% sensitivity and 87.5% specificity (LH60 min/FSH60 min)
for diagnosis of PCOS (Fig. 5A and B). In contrast, base-
line LH/FSH ratio above 2.0, although highly specific, had
a very low sensitivity for the diagnosis of PCOS, i.e. only
23% (Table VI). Interestingly, ROC analysis for the base-
line 17-hydroxy-progesterone to androstendione ratio
demonstrated 68.4% sensitivity and 64.3% specificity for
the diagnosis of PCOS for 17-hydroxy-progesterone [ng/
/mL]/androstendione [ng/mL] ratio > 0.244.
Table IV. Descriptive statistics for LH and FSH concentrations before and after GnRH stimulation in women with PCOS and
controls
Tabela IV. Statystyki opisowe parametrów LH i FSH w teście z GnRH u pacjentek z PCOS i w grupie kontrolnej
Group n Mean Median SD Min Max p value
LH_0’ [IU/L] PCOS 151 9.04 7.80 5.81 0.46 34.00  < 0.00001CONTR 34 4.83 4.57 1.68 1.08 922
LH_30’ [IU/L] PCOS 121 35.38 24.00 31.32 5.92 200.00  < 0.00001CONTR 32 16.30 16.23 6.68 5.34 32.59
LH_60’ [IU/L] PCOS 120 33.86 21.67 31.78 4.87 200.00  < 0.00001CONTR 32 13.45 12.79 5.22 5.01 28.51
FSH_0’ [IU/L] PCOS 148 5.80 5.45 2.48 1.14 24.49 0.047CONTR 32 6.44 6.01 2.02 2.15 12.11
FSH_30’ [IU/L] PCOS 121 8.90 7.83 4.84 3.24 42.58 0.312CONTR 32 8.84 8.11 2.73 3.61 15.28
FSH_60’ [IU/L] PCOS 120 9.95 8.43 8.21 3.58 73.24 0.723CONTR 32 9.04 8.61 3.00 4.05 17.36
Figure 2. Mean LH concentrations [IU/L] during GnRH test in
women with PCOS and in regularly menstruating controls.
Vertical bars represent 95% confidence intervals in the respective
time-points
Rycina 2. Schematyczne przedstawienie rozkładów średnich
wartości LH [jm./L] w teście z GnRH — w grupie z PCOS
i w grupie kontrolnej. Pionowe słupki przedstawiają 95-procentowe
przedziały ufności dla średnich wartości w odpowiednich punktach
czasowych
Figure 3. Mean FSH concentrations [IU/L] during GnRH test
in women with PCOS and in regularly menstruating controls.
Vertical bars represent 95% confidence intervals in the respective
time-points
Rycina 3. Schematyczne przedstawienie rozkładów średnich
wartości poziomów FSH [jm./l] w teście z GnRH — w grupie
z PCOS i w grupie kontrolnej. Pionowe słupki przedstawiają
95-procentowe przedziały ufności dla średnich wartości
w odpowiednich punktach czasowych
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The results of our study suggest that assessment of pi-
tuitary LH and FSH reserve after GnRH stimulation
might be used to confirm the diagnosis of PCOS in some
Table V. Descriptive statistics for concentrations of LH and FSH in relation to their respective baseline values after GnRH
stimulation and for the baseline LH/FSH ratio as well as LH/FSH ratio after GnRH stimulation in women with PCOS and
controls (CONTR)
Tabela V. Statystyki opisowe stężeń LH i FSH w stosunku do wartości wyjściowych po stymulacji przez GnRH, oraz stosunku
LH do FSH w teście z GnRH u pacjentek z PCOS i z grupy kontrolnej (CONTR)
Group n Mean Median SD Min Max p value
LH_30’/0’ PCOS 121 3.99 2.13 7.83 1.08 12.99 0.264CONTR 32 3.89 3.30 2.88 1.59 17.56
LH_60’/0’ PCOS 120 3.76 3.06 2.00 1.10 11.89 0.053CONTR 32 3.28 2.78 2.59 0.94 15.91
FSH_30’/0’ PCOS 121 1.52 1.41 0.53 0.81 5.80 0.211CONTR 32 1.38 1.33 0.21 1.08 1.98
FSH_60’/0’ PCOS 120 1.68 1.47 1.14 0.86 12.96 0.061CONTR 32 1.42 1.39 0.25 0.96 2.13
LH/FSH_0’ PCOS 121 1.59 0.99 1.00 0.23 5.28  < 0.00001CONTR 33 0.76 0.76 0.20 0.26 1.06
LH/FSH_30’ PCOS 121 4.09 3.18 2.99 0.51 16.99  < 0.00001CONTR 32 1.89 1.75 0.79 0.72 5.25
LH/FSH_60’ PCOS 120 3.56 2.77 2.58 0.43 13.65  < 0.00001CONTR 32 1.55 1.44 0.63 0.60 4.24
patients. The study was performed on a large number
of women with PCOS, while the number of controls
(matched for age and BMI) was similar to other leading
studies on gonadotrophin secretion and GnRH stimu-
lation in women with PCOS [10, 19, 20].
It is well known that relative proportions of pitu-
itary secretion of LH and FSH are determined by both
frequency and amplitude of hypothalamic GnRH puls-
es [20, 21]. Very frequent GnRH pulses (i.e. every 8–30
minutes) result in preferential transcription of proteins
for alpha subunit. Pulse frequency of about 30–60 min-
utes results in preferential transcription of LH beta sub-
unit, while less frequent pulses (i.e. every 120–240 min-
utes) lead to predominant transcription of FSH beta
subunit [21]. In the normal menstrual cycle, GnRH pulse
Figure 4. Mean values of LH/FSH ratio during GnRH test in
women with PCOS and in regularly menstruating controls.
Vertical bars represent 95% confidence intervals in the respective
time-points
Rycina 4. Schematyczne przedstawienie rozkładów średnich
wartości stosunków LH/FSH w teście z GnRH — w grupie
z PCOS i w grupie kontrolnej. Pionowe słupki przedstawiają
95-procentowe przedziały ufności dla średnich wartości
w odpowiednich punktach czasowych
Table VI. Sensitivity and specificity of diagnosis of PCOS
based on selected cut-off points of baseline and GnRH-
stimulated LH to FSH ratio
Tabela VI. Czułość i swoistość rozpoznania PCOS na
podstawie oceny stosunku wyjściowego LH do FSH w teście
z GnRH
LH/FSH ratio during Sensitivity Specificity
GnRH test  (%)  (%)
LH/FSH_’0’ > 2.0 23 100
LH/FSH_30’ > 2.11 78.3 87.5
LH/FSH_60’> 1.72 81.7 81.3
17-OHP/androstendione > 0.244 68.4 64.3
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eter confirming the diagnosis of polycystic ovary syn-
drome [6, 35]. There was, however, no agreement as to
the optimal cut-off point for the baseline LH to FSH
ratio, and various authors suggested various cut-off
values (e.g. LH/FSH > 1 [36], LH/FSH > 2 [37] or even
LH/FSH > 3 [38]). Meta-analysis of several studies dem-
onstrated, however, very poor positive predictive val-
ue for baseline LH/FSH ratio i.e. only 18% [39], which
effectively precluded the use of this index as a valid di-
agnostic tool. In our series, 74% of women with PCOS
had higher baseline LH than FSH concentrations, but
for the most frequently quoted cut-off point of LH/FSH
> 2 [37] we obtained only a 23% sensitivity (and 43%
sensitivity for LH/FSH > 1.5), despite high (100%) spec-
ificity for the diagnosis of PCOS.
In such circumstances, there is a question as to why
the sensitivity of baseline LH/FSH ratio is so low de-
spite evidence for increased LH synthesis in PCOS. As
it turns out, women with PCOS, as well as more pro-
nounced insulin resistance and hyperandrogenism,
have relatively lower LH concentrations [20, 40–44],
despite preserved increased GnRH pulse frequency in
those who are more obese and insulin-resistant [42]. The
same phenomenon was also observed in our study,
Figure 5. Receiver operating characteristics (ROC) curve analysis for finding the cut-off for optimal diagnostic accuracy (considered as
the highest proportion of correctly classified subjects) of LH/FSH ratio during GnRH test. The highest sensitivity (78.3% and 81.3%) is
obtained for LH/FSH > 2.110 at 30 minutes of GnRH test (A) and for LH/FSH > 1.723 at 60 minutes of GnRH test (B). Respective
sensitivity is 87.5% and 81.3%. A. ROC curve for assessment of cut-off point for maximal sensitivity for LH/FSH ratio at 30 minutes
of GnRH test; B. ROC curve for assessment of cut-off point for maximal sensitivity for LH/FSH ratio at 60 minutes of GnRH test
Rycina 5. Analiza optymalnej czułości oceny stosunku stężeń LH do FSH w teście z GnRH dla optymalnej swoistości. Najwyższa
czułość diagnostyczna (odpowiednio 78,3% i 81,7%) jest osiągana dla stosunku LH/FSH > 2,110 w 30. minucie testu (A) oraz dla
stosunku LH/FSH > 1,723 w 60. minucie testu z GnRH (B). Odpowiednio swoistość wynosi 87,5 i 81,3%. A. Ocena punktu odcięcia
dla maksymalnej czułości testu z GnRH dla stosunku LH/FSH w 30. minucie testu z GnRH (krzywa ROC); B. Ocena punktu odcięcia
dla maksymalnej czułości testu z GnRH dla stosunku LH/FSH w 60. minucie testu z GnRH (krzywa ROC)
frequency increases from about 90-100 minutes to about
every 60 minutes through a follicular phase. Gradual
increase in GnRH pulse frequency facilitates LH secre-
tion culminating in an ovulatory LH surge [22, 23]. In
contrast, increased progesterone secretion in a luteal
phase results in an increase in FSH synthesis as a result
of less frequent hypothalamic GnRH secretion (approx-
imately one pulse every 3–5 hours), through mecha-
nisms involving opioid receptors [24–27] and possibly
other factors such as kisspeptin [28].
PCOS is characterised by an increase in both fre-
quency and amplitude of hypothalamic GnRH pulses,
generated at a frequency of about once every 60 min-
utes, i.e. the frequency observed only in the late follicu-
lar phase in healthy women [29, 30]. This is accompa-
nied by resistance to inhibitory effects of progesterone
on the frequency of hypothalamic GnRH secretion [31,
32]. Furthermore, a similar situation has been observed
in hyperandrogenic adolescent girls even in the setting
of regular menstrual cycles [33, 34].
As a result of the above described phenomena, PCOS
is characterised by a relative overproduction of LH in
relation to FSH. Hence, an increased LH to FSH ratio
was once suggested to be used as an additional param-
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where there was a weak (r = –0.21), but still significant
(p < 0.05) correlation between BMI and baseline LH
concentrations as well as between LH and insulin resis-
tance index (r = –0.31).
In our study, a relative increase of LH concen-
trations is proportional to (higher) baseline LH concen-
trations in women with PCOS, resulting in higher stim-
ulated LH concentrations in this group, albeit without
significant differences in either baseline or stimulated
FSH levels. This is in accordance with results of other
studies [20, 45]. Such a situation results in a more pro-
nounced increase of GnRH-stimulated LH/FSH ratio in
women with PCOS than in controls. This, in turn, leads
to a dramatic (almost four-fold) increase in the diag-
nostic sensitivity of GnRH-stimulated LH/FSH ratio. For
instance, results of ROC analysis reveal 81.7% sensitiv-
ity with 81.3% specificity for LH/FSH ratio above
1.72 post GnRH stimulation. This is much better than
sensitivity of total testosterone assays (around 40% [46])
and is even higher than the sensitivity of all androgen
analyses (58.1%) observed in our study. One must be
also aware that assessment of androgen concentrations
within the female range by the means of standard an-
drogen assays is fraught with methodological problems,
including very high coefficients of variation reaching
as much as around 35% [47–49], while the more accu-
rate mass spectrometry method [50] is still very rarely
used in Poland. If such assay-dependent variability were
employed e.g for the diagnosis of diabetes, than for fast-
ing glucose concentration of 136 mg/dL, the obtained
results would range from 88 mg/dL (entirely normal)
to as much as 183 mg/dL (poorly controlled diabetes)!
According to the current consensus [4], diagnosis of
PCOS requires exclusion of other causes of oligo-/amen-
orrhoea and hyperandrogenism (e.g. hyperprolacti-
naemia, hypercortisolaemia, late-onset congenital ad-
renal hyperplasia). In such a context, we note that in
our study more than 40% of the women with PCOS
according to the Rotterdam criteria [4] had androgens
within the reference range i.e. on the basis of coexist-
ence of oligo/amenorrhoea and polycystic ovaries, they
would not be classified as having PCOS according to
the recent Androgen Excess Society criteria [51].
We suggest that assessment of GnRH-stimulated
LH/FSH ratio may be potentially useful, particularly in
that group of women.
As we have already described, Barnes et al. [9] and
Ehrmann et al. [10] have suggested that the GnRH test
might be useful in the diagnosis of PCOS, but the issue
of the optimal GnRH test protocol remains unresolved.
In particular, there is a question whether GnRH test
should be performed according to the protocol involv-
ing assessment of 17-hydroxy-progesterone/androsten-
dione ratio around 24-hours post GnRH agonist stimu-
lation, as described before [9, 10]. As it turns out, how-
ever, increased GnRH stimulated 17-hydroxy-progest-
erone/androstendione ratio is observed only in slightly
less than 50% of women with PCOS [52]. That is also in
accordance with earlier studies involving ovarian and
adrenal vein catheterisation [5], where frank ovarian
hyperandrogenism was observed in only around 50%
(10/21) of women with PCOS. Interestingly this is slight-
ly lower than the diagnostic utility of baseline 17-hy-
droxy-progesterone/androstendione ratio above
0.244 (ROC analysis) observed in our study, where we
observed 68.4% sensitivity and 64.3% specificity for the
diagnosis of PCOS.
In summary, our study demonstrated a marked in-
crease in GnRH-stimulated LH/FSH ratio in women
with PCOS diagnosed according to the Rotterdam cri-
teria [4]. Although the results of our study need to be
confirmed in women with hyperandrogenism, polycys-
tic ovaries and regular menses, we suggest that assess-
ment of GnRH stimulated LH/FSH ratio might be po-
tentially useful as a confirmatory test for the diagnosis
of PCOS in some patients, such as women with poly-
cystic ovaries and oligo-/amenorrhoea, but with andro-
gens within the reference range. In such cases, LH/FSH
ratio above 2.11 at 30 minutes post GnRH stimulation,
or above 1.72 at 60 minutes post GnRH stimulation,
would support a diagnosis of PCOS.
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